Optimizing Liquid Biopsy Workflows From Sample Preparation to Analysis

Using our sample purification solutions with a Thermo Scientific KingFisher instrument can decrease touch-points by as much as 75%. Automated sample preparation Thermo Scientific™ KingFisher™ automated purification systems with MagMAX or Dynabeads solutions Supporting the trusted diagnostic test: tissue biopsy As liquid biopsy evolves, tissue biopsy continues to be widely used in confirming cancer diagnosis. Advancements in liquid biopsy often rely on solid tumor biopsies for complementary studies, which makes overcoming typical challenges with tissue sample types crucial. Maintaining tissue integrity and obtaining quality nucleic acids for downstream analysis can provide researchers with a depth of molecular information directly from the malignant tissue. Nucleic acid isolation from formaldehyde-fixed or formalin-fixed, paraffin-embedded (FFPE) tissue Applied Biosystems™ MagMAX™ FFPE DNA/RNA Ultra Kit FFPE deparaffinization Applied Biosystems™ AutoLys M Tubes and Caps Nucleic acid isolation from fresh-frozen tissues Applied Biosystems™ MagMAX™ DNA Multi-Sample Ultra 2.0 Kit Cancer research Nucleic acid isolation Molecular profiling of nucleic acids found in blood, plasma, serum, and other liquid biopsy samples may enable researchers to detect cancer-specific variants, providing potential early warning signs of tumor growth or recurrence. Total nucleic acid analysis may provide a more thorough understanding of gene expression of cancer-associated variants, potentially yielding new insights into individual cancer risk and immune response. Cell-free nucleic acid isolation Applied Biosystems™ MagMAX™ Cell-Free DNA Isolation Kit Applied Biosystems™ MagMAX™ Cell-Free Total Nucleic Acid Isolation Kit Sequential DNA and RNA isolation Applied Biosystems™ MagMAX™ Sequential DNA/RNA Kit Genomic DNA isolation Applied Biosystems™ MagMAX™ DNA Multi-Sample Ultra 2.0 Kit Total RNA isolation Applied Biosystems™ MagMAX™ mirVana™ Total RNA Isolation Kit Circulating tumor cells and extracellular vesicle isolation Circulating tumor cells (CTCs) and extracellular vesicles (EVs) are released by cancer cells into the bloodstream. When found in body fluids, these biomolecules can potentially reveal signs of metastasis, rates of cancer cell growth, or response to treatment. The cargos found in EVs enable research analysis into the prevalence and identity of cancer-specific bioactive DNA, RNA, and protein as they are transported between primary and secondary tumors, which may yield understandings into cancer progression and therapeutic development. Circulating tumor cell isolation Invitrogen™ Dynabeads™ magnetic beads Tumor cell enrichment Invitrogen™ Dynabeads™ Epithelial Enrich magnetic beads Exosome isolation Invitrogen™ Dynabeads™ Intact Virus Enrichment beads Thermo Fisher Scientific empowers liquid biopsy and oncology research applications with flexible and comprehensive solutions designed to support cancer analysis workflows at every stage, ensuring that researchers have tools they need to conduct thorough and accurate studies. Paving the way Optimizing liquid biopsy workflows from sample preparation to analysis For Research Use Only. Not for use in diagnostic procedures. © 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. EXT6943 Explore our end-to-end workflow solutions thermofisher.com/cancerworkflows Genetic analysis to decode malignancies Innovation in molecular analysis technologies have the potential to take liquid biopsy techniques into clinical practice. Specific and sensitive assays can provide researchers with the ability to detect low-level targets found in liquid biopsy samples. Automated platforms can help provide added efficiency and the consistency needed for clinical translational research into cancer diagnostic development and personalized treatment studies. Nucleic acid and protein quantification Invitrogen™ Qubit™ Fluorometers and assays Thermo Scientific™ NanoDrop™ microvolume spectrophotometers Digital PCR (dPCR) Applied Biosystems™ Absolute Q™ dPCR systems, assays, and reagents High-resolution capillary electrophoresis Applied Biosystems™ genetic analyzers, kits, and reagents Applied Biosystems™ TrueMark™ MSI Assay Next-generation sequencing (NGS) library preparation Ion Torrent™ Ion Chef™ System Applied Biosystem™ MagMAX™ Pure Bind beads Invitrogen™ Dynabeads™ Streptavidin for Target Enrichment NGS sequencing analysis Applied Biosystems™ Ion GeneStudio™ S5 systems Ion Torrent™ Oncomine™ assays Ion Torrent™ Ion AmpliSeq™ HD panels Accelerating discoveries with immuno-oncology, proteomics, and cell analysis Success in understanding complex interactions and characteristics of cancer and the advancement of immuno-oncology therapies relies on a knowledge of the underlying interactions of cancer cells and tumor microenvironment. Evolving research in proteomic and multi-omic analyses may support complex development of targeted therapy for future clinical use. Protein and cell detection and analysis Western blotting solutions Proteomics mass spectometry Flow cytometry Cell function assays Cell imaging Immunoassays for immuno-oncology Immunoassays for cancer progression Estimates suggest that approximately 1 in 5 people will develop cancer in their lifetime.1 Estimates suggest that approximately 1 in 5 people will develop cancer in their lifetime.1 References 1. Bray F, Laversanne M, Sung H, et al. (2022) CA Cancer J Clin 74(3):229-263. 2. Blood Cancer UK (2019). Accessed August 1 2024. https://bloodcancer.org. uk/news/blood-cancer-survival-rising-faster-other-common-cancers/ 3. Leukemia & Lymphoma Society (2023). https://www.lls.org/ facts-and-statistics/facts-and-statistics-overview 4. Hemminki K, Hemminki J, Försti A, et al. (2023) Leukemia 37:854–863 (2023). 5. American Association for Cancer Research. Cancer progress report 2023. https://cancerprogressreport.aacr.org/progress/ Liquid biopsy has emerged as a powerful complement to conventional solid tumor biopsies by enabling cancer investigation through a less-invasive process of collecting blood and other body fluids. Analyte extraction tools with high purity and yield ensure enough sample is available for analysis of low concentration analytes such as ctDNA and circulating tumor cells (CTCs). Sensitive genomic and proteomic analysis technologies can help reveal potential biomarkers for dynamic tumor characterization, progression, and treatment response. When cancer is diagnosed early, the overall 5-year cancer-specific survival rate is 4 times higher than when cancer is diagnosed late.5 Eliminate exposure to organic solvents with AutoLys M Tubes and Caps and MagMAX FFPE kits. A broad range of protein and cellular analysis tools help paint a more holistic picture. Studies suggest that 5-year survival rates for blood cancers have risen significantly over the past 40 years.2,3,4 Detect and quantitate rare targets with mutation allele frequencies as low as 0.1% with Absolute Q dPCR systems.